Business Description
Agenus Inc
NAICS : 325414
SIC : 2836
ISIN : US00847G7051
Description
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.16 | |||||
| Equity-to-Asset | -0.83 | |||||
| Debt-to-Equity | -0.34 | |||||
| Debt-to-EBITDA | -0.87 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -11.2 | |||||
| Beneish M-Score | -1.22 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -5.1 | |||||
| 3-Year EBITDA Growth Rate | 15 | |||||
| 3-Year EPS without NRI Growth Rate | 12.4 | |||||
| 3-Year FCF Growth Rate | 7.5 | |||||
| 3-Year Book Growth Rate | 26.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 16.4 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 32.41 | |||||
| 9-Day RSI | 33.91 | |||||
| 14-Day RSI | 36.06 | |||||
| 6-1 Month Momentum % | -40.19 | |||||
| 12-1 Month Momentum % | -49.36 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.37 | |||||
| Quick Ratio | 0.37 | |||||
| Cash Ratio | 0.35 | |||||
| Days Sales Outstanding | 13.45 | |||||
| Days Payable | 93.72 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -26.2 | |||||
| Shareholder Yield % | -75.42 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -25.07 | |||||
| Operating Margin % | -71.28 | |||||
| Net Margin % | -139.99 | |||||
| FCF Margin % | -117.28 | |||||
| ROA % | -70.63 | |||||
| ROIC % | -32.07 | |||||
| 3-Year ROIIC % | -26.67 | |||||
| ROC (Joel Greenblatt) % | -65.23 | |||||
| ROCE % | -135.2 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.09 | |||||
| EV-to-EBIT | -0.5 | |||||
| EV-to-Forward-EBIT | -0.93 | |||||
| EV-to-EBITDA | -0.58 | |||||
| EV-to-Revenue | 0.34 | |||||
| EV-to-Forward-Revenue | 1.27 | |||||
| EV-to-FCF | -0.29 | |||||
| Price-to-Median-PS-Value | 0.01 | |||||
| Earnings Yield (Greenblatt) % | -200 | |||||
| FCF Yield % | -277.95 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Agenus Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 147.233 | ||
| EPS (TTM) (€) | -5.199 | ||
| Beta | 0 | ||
| Volatility % | 49.87 | ||
| 14-Day RSI | 36.06 | ||
| 14-Day ATR (€) | 0.643903 | ||
| 20-Day SMA (€) | 9.3827 | ||
| 12-1 Month Momentum % | -49.36 | ||
| 52-Week Range (€) | 7.404 - 37.67 | ||
| Shares Outstanding (Mil) | 20.95 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Agenus Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Agenus Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Agenus Inc Frequently Asked Questions
What is Agenus Inc(STU:AJ8)'s stock price today?
The current price of STU:AJ8 is €7.95. The 52 week high of STU:AJ8 is €37.67 and 52 week low is €7.40.
When is next earnings date of Agenus Inc(STU:AJ8)?
The next earnings date of Agenus Inc(STU:AJ8) is 2025-02-12 Est..
Does Agenus Inc(STU:AJ8) pay dividends? If so, how much?
Agenus Inc(STU:AJ8) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers